Galderisi Alfonso, Sherr Jennifer L
Pediatr Ann. 2019 Aug 1;48(8):e311-e318. doi: 10.3928/19382359-20190725-03.
Intensive insulin treatment and frequent self-monitoring of blood glucose (SMBG) have been recognized as pillars of diabetes treatment. Many patients with type 1 diabetes (T1D) struggle to achieve targeted glycemic control. Technology has vastly changed how these tenets to treatment can occur. Continuous subcutaneous insulin infusion (CSII) pumps and continuous glucose monitoring (CGM) can be used in place of their counterparts, multiple daily injections and SMBG. We present a review of CSII, CGM, and of different levels of integration among these two therapies, ranging from low glucose suspension devices to hybrid closed loop insulin delivery. Analysis of the various tools, their effect on glycemic control, and a guide to integrate them into pediatric clinical practice is presented. Although a cure for T1D remains the ultimate goal, technology holds the promise of keeping youth with T1D in targeted control and minimize the burden of this chronic medical condition. [Pediatr Ann. 2019;48(8):e311-e318.].
强化胰岛素治疗和频繁的血糖自我监测（SMBG）已被视为糖尿病治疗的支柱。许多1型糖尿病（T1D）患者难以实现目标血糖控制。技术极大地改变了这些治疗原则的实施方式。持续皮下胰岛素输注（CSII）泵和持续葡萄糖监测（CGM）可用于替代每日多次注射和SMBG。我们对CSII、CGM以及这两种疗法之间不同程度的整合进行了综述，范围从低血糖暂停装置到混合闭环胰岛素输送。介绍了对各种工具的分析、它们对血糖控制的影响以及将它们整合到儿科临床实践中的指南。尽管治愈T1D仍然是最终目标，但技术有望使患有T1D的青少年维持目标控制，并将这种慢性疾病的负担降至最低。[《儿科年鉴》。2019年；48(8):e311 - e318。]
